HRP20160594T1 - Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima - Google Patents
Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima Download PDFInfo
- Publication number
- HRP20160594T1 HRP20160594T1 HRP20160594TT HRP20160594T HRP20160594T1 HR P20160594 T1 HRP20160594 T1 HR P20160594T1 HR P20160594T T HRP20160594T T HR P20160594TT HR P20160594 T HRP20160594 T HR P20160594T HR P20160594 T1 HRP20160594 T1 HR P20160594T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- peptide
- composition
- polypeptide
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Sastav, naznačen time, da obuhvaća najmanje jedan peptid ili polipeptid koji sadrži sljedeću aminokiselinsku sekvencu
[image]
gdje
X1 je bilo koji aminokiselinski ostatak,
X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K), arginin (R), alanin (A) i histidin (H),
X3 je aminokiselinski ostatak odabran iz skupine koju čine asparagin (N), glutamin (Q), serin (S), glicin (G) i alanin (A), poželjno asparagin (N), serin (S), glicin (G) i alanin (A),
X4 je aminokiselinski ostatak odabran iz skupine koju čine glutaminska kiselina (E), asparaginska kiselina (D) i alanin (A),
X5 je aminokiselinski ostatak odabran iz skupine koju čine glutaminska kiselina (E) i asparaginska kiselina (D),
X6 je aminokiselinski ostatak odabran iz skupine koju čine alanin (A) i tirozin (Y),
X7 je bilo koji aminokiselinski ostatak,
n i m su međusobno neovisno 0 ili neki cijeli broj veći od 0,
i čime aminokiselinska sekvenca prema formuli I nije identična sa sedmomernim fragmentom polipeptida od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP, ili ga ne sadrži,
gdje navedeni najmanje jedan peptid ili polipeptid ima kapacitet za vezanje na protutijelo specifično za epitop od alfa-sinukleina koji ima aminokiselinsku sekvencu KNEEGAP,
te time, da je za uporabu u prevenciji i/ili liječenju sinukleinopatija.
2. Sastav za uporabu prema zahtjevu 1, naznačen time, da X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K) i arginin (R) i/ili X6 je alanin (A).
3. Sastav za uporabu prema zahtjevu 1 ili 2, naznačen time, da peptid ili polipeptid obuhvaća aminokiselinsku sekvencu odabranu iz skupine koju čine (X1)nKNDEGAP(X7)m, (X1)nANEEGAP(X7)m, (X1)nKAEEGAP(X7)m,
(X1)nKNAEGAP(X7)m, (X1)nRNEEGAP(X7)m, (X1)nHNEEGAP(X7)m,
(X1)nKNEDGAP(X7)m, (X1)nKQEEGAP(X7)m, (X1)nKSEEGAP(X7)m,
(X1)nKNDDGAP(X7)m, (X1)nRNDEGAP(X7)m, (X1)nRNEDGAP(X7)m,
(X1)nRQEEGAP(X7)m, (X1)nRSEEGAP(X7)m, (X1)nANDEGAP(X7)m,
(X1)nANEDGAP(X7)m, (X1)nHSEEGAP(X7)m, (X1)nASEEGAP(X7)m,
(X1)nHNEDGAP(X7)m, (X1)nHNDEGAP(X7)m, (X1)nRNAEGAP(X7)m,
(X1)nHNAEGAP(X7)m, (X1)nKSAEGAP(X7)m, (X1)nKSDEGAP(X7)m,
(X1)nKSEDGAP(X7)m, (X1)nRQDEGAP(X7)m, (X1)nRQEDGAP(X7)m,
(X1)nHSAEGAP(X7)m, (X1)nRSAEGAP(X7)m, (X1)nRSDEGAP(X7)m,
(X1)nRSEDGAP(X7)m, (X1)nHSDEGAP(X7)m, (X1)nHSEDGAP(X7)m,
(X1)nRQDDGAP(X7)m, poželjno (X1)nKNDEGAP(X2)m, (X1)nRNEEGAP(X2)m, (X1)nRNDEGAP(X2)m, (X1)nKNAEGAP(X2)m, (X1)nKSDEGAP(X2)m, (X1)nRNAEGAP(X2)m ili (X1)nRSEEGAP(X2)m.
4. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da n i/ili m su 1, a X1 i/ili X7 su cistein (C).
5. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da peptid ili polipeptid sadrži od 7 do 30, poželjno od 7 do 20, još bolje od 7 do 16, te najbolje 8 aminokiselinskih ostataka.
6. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je sinukleinopatija odabrana iz skupine koju čine poremećaji s Lewyjevim tijelima (LBD), posebno Parkinsonova bolest (PD), Parkinsonova bolest s demencijom (PDD) i demencija s Lewyjevim tijelima (DLB), kao i višestruka sistemska atrofija (MSA) ili neurodegeneracija s akumuliranjem željeza u mozgu, tipa I (NBIA tip I).
7. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je najmanje jedan peptid ili polipeptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
8. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da je najmanje jedan peptid ili polipeptid formuliran za intravenoznu, subkutanu, intradermalnu ili intramuskularnu primjenu.
9. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je najmanje jedan peptid ili polipeptid formuliran s jednim pomoćnim sredstvom, poželjno s aluminijevim hidroksidom.
10. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se najmanje jedan peptid ili polipeptid nalazi u sastavu u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, posebno od 100 ng do 100 μg.
11. Peptid, naznačen time, da ima aminokiselinsku sekvencu odabranu iz skupine koju čine (X1)nKNDEGAP(X7)m, (X1)nANEEGAP(X7)m, (X1)nKAEEGAP(X7)m, (X1)nKNAEGAP(X7)m, (X1)nRNEEGAP(X7)m, (X1)nHNEEGAP(X7)m, (X1)nKNEDGAP(X7)m, (X1)nKQEEGAP(X7)m, (X1)nKSEEGAP(X7)m, (X1)nKNDDGAP(X7)m, (X1)nRNDEGAP(X7)m, (X1)nRNEDGAP(X7)m, (X1)nRQEEGAP(X7)m, (X1)nRSEEGAP(X7)m, (X1)nANDEGAP(X7)m, (X1)nANEDGAP(X7)m, (X1)nHSEEGAP(X7)m, (X1)nASEEGAP(X7)m, (X1)nHNEDGAP(X7)m, (X1)nHNDEGAP(X7)m, (X1)nRNAEGAP(X7)m, (X1)nHNAEGAP(X7)m, (X1)nKSAEGAP(X7)m, (X1)nKSDEGAP(X7)m, (X1)nKSEDGAP(X7)m, (X1)nRQDEGAP(X7)m,
(X1)nRQEDGAP(X7)m, (X1)nHSAEGAP(X7)m, (X1)nRSAEGAP(X7)m,
(X1)nRSDEGAP(X7)m, (X1)nRSEDGAP(X7)m, (X1)nHSDEGAP(X7)m,
(X1)nHSEDGAP(X7)m i (X1)nRQDDGAP(X7)m, pri čemu su X1 i X7 cistein,
dok su n i m neovisno 0 ili 1.
12. Peptid prema zahtjevu 11, naznačen time, da je peptid spojen na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
13. Peptid prema zahtjevu 11 ili 12, naznačen time, da se upotrebljava u prevenciji i/ili liječenju sinukleinopatija.
14. Farmaceutska formulacija, naznačena time, da obuhvaća najmanje jedan peptid prema zahtjevu 11 ili 12.
15. Farmaceutska formulacija prema zahtjevu 14, naznačena time, da se upotrebljava kao cjepivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0132409A AT508638B1 (de) | 2009-08-21 | 2009-08-21 | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| PCT/AT2010/000303 WO2011020133A1 (en) | 2009-08-21 | 2010-08-20 | Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160594T1 true HRP20160594T1 (hr) | 2016-07-29 |
Family
ID=42940852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160594TT HRP20160594T1 (hr) | 2009-08-21 | 2010-08-20 | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8828942B2 (hr) |
| EP (1) | EP2467153B1 (hr) |
| JP (2) | JP2013502379A (hr) |
| KR (2) | KR101517447B1 (hr) |
| CN (1) | CN102596224B (hr) |
| AT (1) | AT508638B1 (hr) |
| AU (1) | AU2010283948B2 (hr) |
| BR (1) | BR112012003800A2 (hr) |
| CA (1) | CA2771429A1 (hr) |
| CY (1) | CY1117582T1 (hr) |
| DK (1) | DK2467153T3 (hr) |
| ES (1) | ES2573662T3 (hr) |
| HR (1) | HRP20160594T1 (hr) |
| HU (1) | HUE027563T2 (hr) |
| IL (1) | IL218207A0 (hr) |
| MX (1) | MX2012002153A (hr) |
| PL (1) | PL2467153T3 (hr) |
| PT (1) | PT2467153E (hr) |
| RU (1) | RU2532351C2 (hr) |
| SI (1) | SI2467153T1 (hr) |
| WO (1) | WO2011020133A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2579042T3 (da) | 2011-10-04 | 2014-07-21 | Affiris Ag | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659906A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| LT3071597T (lt) | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| AU2016348610B2 (en) | 2015-11-03 | 2023-08-31 | Ac Immune Sa | Method for vaccination against a self-antigen in a human patient |
| KR101726549B1 (ko) | 2016-06-29 | 2017-04-12 | 정상문 | 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식 |
| KR102087494B1 (ko) | 2018-03-15 | 2020-03-10 | 정상문 | 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법 |
| PH12021550898A1 (en) | 2018-12-20 | 2022-05-02 | Saiba AG | Virus-like particles of cmv modified by fusion |
| EP4190797A4 (en) | 2020-07-29 | 2024-09-04 | Tohoku University | PEPTIDE USED TO PREVENT OR TREAT SYNUCLEINOPATHY |
| JP2023536497A (ja) | 2020-08-04 | 2023-08-25 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
| WO2022218928A1 (en) | 2021-04-12 | 2022-10-20 | Saiba AG | Modified virus-like particles of bacteriophage ap205 |
| TW202306966A (zh) * | 2021-06-18 | 2023-02-16 | 日商住友製藥股份有限公司 | 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物 |
| AU2023219059A1 (en) | 2022-02-09 | 2024-07-25 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
| US20250186595A1 (en) | 2022-02-28 | 2025-06-12 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
| US20250186596A1 (en) | 2022-02-28 | 2025-06-12 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007325595A (ja) * | 2000-12-22 | 2007-12-20 | Locomogene Inc | 滑膜細胞タンパク質 |
| WO2003045128A2 (en) * | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| ES2640669T3 (es) * | 2003-05-19 | 2017-11-03 | Prothena Biosciences Limited | Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy |
| WO2004113535A1 (ja) | 2003-06-22 | 2004-12-29 | Koji Sode | 凝集抑制作用を有するシヌクレイン変異体 |
| WO2006004066A1 (ja) * | 2004-07-02 | 2006-01-12 | Locomogene, Inc. | S1-5を含有するタンパク質製剤 |
| EA013752B1 (ru) * | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| ZA200701531B (en) | 2004-08-09 | 2009-03-25 | Elan Pharm Inc | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CA2633399C (en) * | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| HRP20150831T1 (hr) * | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
-
2009
- 2009-08-21 AT AT0132409A patent/AT508638B1/de not_active IP Right Cessation
-
2010
- 2010-08-20 SI SI201031190A patent/SI2467153T1/sl unknown
- 2010-08-20 KR KR1020127007123A patent/KR101517447B1/ko not_active Expired - Fee Related
- 2010-08-20 ES ES10747562.6T patent/ES2573662T3/es active Active
- 2010-08-20 DK DK10747562.6T patent/DK2467153T3/en active
- 2010-08-20 JP JP2012524998A patent/JP2013502379A/ja active Pending
- 2010-08-20 MX MX2012002153A patent/MX2012002153A/es active IP Right Grant
- 2010-08-20 EP EP10747562.6A patent/EP2467153B1/en active Active
- 2010-08-20 US US13/391,552 patent/US8828942B2/en not_active Expired - Fee Related
- 2010-08-20 RU RU2012110582/15A patent/RU2532351C2/ru not_active IP Right Cessation
- 2010-08-20 HR HRP20160594TT patent/HRP20160594T1/hr unknown
- 2010-08-20 HU HUE10747562A patent/HUE027563T2/en unknown
- 2010-08-20 CA CA2771429A patent/CA2771429A1/en not_active Abandoned
- 2010-08-20 PL PL10747562.6T patent/PL2467153T3/pl unknown
- 2010-08-20 WO PCT/AT2010/000303 patent/WO2011020133A1/en active Application Filing
- 2010-08-20 PT PT107475626T patent/PT2467153E/pt unknown
- 2010-08-20 CN CN201080047744.9A patent/CN102596224B/zh not_active Expired - Fee Related
- 2010-08-20 BR BR112012003800A patent/BR112012003800A2/pt not_active IP Right Cessation
- 2010-08-20 KR KR1020147028566A patent/KR20140141651A/ko not_active Ceased
- 2010-08-20 AU AU2010283948A patent/AU2010283948B2/en not_active Ceased
-
2012
- 2012-02-20 IL IL218207A patent/IL218207A0/en unknown
-
2014
- 2014-09-03 JP JP2014179547A patent/JP5901714B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-01 CY CY20161100480T patent/CY1117582T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2467153T1 (sl) | 2016-07-29 |
| KR20120059562A (ko) | 2012-06-08 |
| DK2467153T3 (en) | 2016-06-06 |
| KR101517447B1 (ko) | 2015-05-28 |
| WO2011020133A1 (en) | 2011-02-24 |
| US8828942B2 (en) | 2014-09-09 |
| CN102596224A (zh) | 2012-07-18 |
| CA2771429A1 (en) | 2011-02-24 |
| HUE027563T2 (en) | 2016-10-28 |
| AU2010283948B2 (en) | 2015-01-22 |
| BR112012003800A2 (pt) | 2016-11-22 |
| AT508638B1 (de) | 2011-08-15 |
| MX2012002153A (es) | 2012-03-14 |
| KR20140141651A (ko) | 2014-12-10 |
| US20120156234A1 (en) | 2012-06-21 |
| JP2013502379A (ja) | 2013-01-24 |
| JP2015038078A (ja) | 2015-02-26 |
| ES2573662T3 (es) | 2016-06-09 |
| CY1117582T1 (el) | 2017-04-26 |
| RU2012110582A (ru) | 2013-09-27 |
| AU2010283948A1 (en) | 2012-03-29 |
| EP2467153B1 (en) | 2016-03-02 |
| JP5901714B2 (ja) | 2016-04-13 |
| CN102596224B (zh) | 2015-12-09 |
| EP2467153A1 (en) | 2012-06-27 |
| IL218207A0 (en) | 2012-04-30 |
| RU2532351C2 (ru) | 2014-11-10 |
| PL2467153T3 (pl) | 2016-09-30 |
| AT508638A1 (de) | 2011-03-15 |
| PT2467153E (pt) | 2016-06-08 |
| HK1170658A1 (zh) | 2013-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160594T1 (hr) | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima | |
| HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
| HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
| RU2011100125A (ru) | Соединения для лечения амилоидозов | |
| RU2013154066A (ru) | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения | |
| PH12019500074A1 (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| RU2021105821A (ru) | Соединения, связывающие рецептор il-2 | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| JP2013543497A5 (hr) | ||
| RU2010143597A (ru) | Стабилизированные жидкие ферментные композиции | |
| RU2014114506A (ru) | Вакцина | |
| RU2010101232A (ru) | Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту | |
| JP2011522842A5 (hr) | ||
| WO2015157508A1 (en) | Peptidomimetic macrocycles with pth activity | |
| CA2092075A1 (en) | Peptide-based inhibitors of hiv replication | |
| RU2014131605A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| RU2009105176A (ru) | Дипептидные миметики нейротрофинов ngf и bdnf | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| HRP20240906T1 (hr) | Agonisti crf2 receptora i njihova primjena u terapiji | |
| JPH07324097A (ja) | インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類 | |
| RU2011153023A (ru) | Конъюгат амилоидного пептида и композиция на его основе для лечения или предупреждения заболевания, ассоциированного с отложением амилоидных белков | |
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). |